Trial Profile
Suvorexant: A Dual Orexin Receptor Antagonist for Treating Sleep Disturbance in Posttraumatic Stress
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 21 Dec 2023
Price :
$35
*
At a glance
- Drugs Suvorexant (Primary)
- Indications Insomnia; Post-traumatic stress disorders
- Focus Therapeutic Use
- 07 Jan 2021 Planned End Date changed from 30 Sep 2023 to 31 Dec 2024.
- 07 Jan 2021 Planned primary completion date changed from 30 Sep 2023 to 31 Dec 2024.
- 04 Sep 2019 Status changed from not yet recruiting to recruiting.